Investigational Drug Information for Guadecitabine
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Guadecitabine?
Guadecitabine is an investigational drug.
There have been 28 clinical trials for Guadecitabine.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 19th 2015.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Preleukemia. The leading clinical trial sponsors are Astex Pharmaceuticals, Astex Pharmaceuticals, Inc., and National Cancer Institute (NCI).
There are nine US patents protecting this investigational drug and one hundred and fifty-two international patents.
Summary for Guadecitabine
| US Patents | 9 |
| International Patents | 152 |
| US Patent Applications | 40 |
| WIPO Patent Applications | 24 |
| Japanese Patent Applications | 18 |
| Clinical Trial Progress | Phase 3 (2015-03-19) |
| Vendors | 16 |
Recent Clinical Trials for Guadecitabine
| Title | Sponsor | Phase |
|---|---|---|
| A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndro | M.D. Anderson Cancer Center | Phase 2 |
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | National Cancer Institute (NCI) | Phase 2 |
| A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 | Astex Pharmaceuticals, Inc. | Phase 2 |
Clinical Trial Summary for Guadecitabine
Top disease conditions for Guadecitabine
Top clinical trial sponsors for Guadecitabine
US Patents for Guadecitabine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Guadecitabine | See Plans and Pricing | Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | See Plans and Pricing |
| Guadecitabine | See Plans and Pricing | Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | See Plans and Pricing |
| Guadecitabine | See Plans and Pricing | Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | See Plans and Pricing |
| Guadecitabine | See Plans and Pricing | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (Tokyo, JP) | See Plans and Pricing |
| Guadecitabine | See Plans and Pricing | Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Guadecitabine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Guadecitabine | European Patent Office | EP3129380 | 2034-04-11 | See Plans and Pricing |
| Guadecitabine | Japan | JP2017510610 | 2034-04-11 | See Plans and Pricing |
| Guadecitabine | Japan | JP6577958 | 2034-04-11 | See Plans and Pricing |
| Guadecitabine | World Intellectual Property Organization (WIPO) | WO2015155332 | 2034-04-11 | See Plans and Pricing |
| Guadecitabine | Argentina | AR106314 | 2035-10-09 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
